Literature DB >> 24332508

Radical cystectomy in a Dutch University hospital: long-term outcomes and prognostic factors in a homogeneous surgery-only series.

Harman M Bruins1, Tom J H Arends1, Mijke Pelkman1, Christina A Hulsbergen-van de Kaa2, Antoine G van der Heijden1, J Alfred Witjes3.   

Abstract

BACKGROUND: The aim of this study was to present survival outcomes and identify prognostic factors in patients undergoing radical cystectomy (RC) for urothelial bladder cancer (UBC) in a homogeneous surgery-only series. PATIENTS AND METHODS: Patients who underwent RC for UBC with intent-to-cure between January 1998 and December 2010 without neoadjuvant or adjuvant treatment were included in this retrospective study. Clinical and histopathologic data were collected and institutional review board approval was obtained. Outcomes of interest were 30-day mortality (30dM), RFS, and OS. Univariable and multivariable analysis were performed. Median follow-up was 9.1 years.
RESULTS: Two hundred forty-five patients were included with a median age of 65 years (range, 34-92 years). 30dM rate was in 5 out of 245 patients (2.0%) and 5-year RFS and OS rates were 67% and 58%, respectively. A total of 223 patients (91%) underwent lymph node (LN) dissection. Median number of removed and positive LNs were 9 and 1.5, respectively. Variables independently associated with decreased OS and RFS were tumor stage and LN status. In addition, positive soft tissue surgical margin (STSM) status was independently associated with decreased OS. In LN-positive patients, presence of extranodal extension (ENE) was associated with decreased RFS (39.7% vs. 7.3%; P = .005).
CONCLUSION: Radical cystectomy for UBC was associated with low perioperative mortality rate and provided 5-year disease control in approximately two-thirds of patients. Independent prognostic factors included tumor stage, LN status (RFS and OS), and STSM status (OS). Presence of ENE in LN-positive patients was univariably associated with decreased RFS and OS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical outcome; Lymph node dissection; Muscle-invasive bladder cancer; Urinary bladder cancer; Urothelial carcinoma

Mesh:

Year:  2013        PMID: 24332508     DOI: 10.1016/j.clgc.2013.11.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  6 in total

1.  Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the bladder.

Authors:  Ülkü Küçük; Sümeyye Ekmekçi; Ebru Çakır; Zübeyde Ekin; Batuhan Ergani; Gökhan Rahmi Ekin
Journal:  Turk J Urol       Date:  2018-08-31

2.  Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis.

Authors:  Xuwei Hong; Tieqiu Li; Fengsheng Ling; Dashan Yang; Lina Hou; Fei Li; Wanlong Tan
Journal:  Oncotarget       Date:  2017-03-07

3.  Is survival after radical cystectomy for bladder cancer in Saudi patients different from that of Western patients?

Authors:  Alaa Mokhtar; Mohamed Matar Al; Waleed Mohamad Al; Khalid Al Othman; Said A Kattan; Mohammed Faihan Al
Journal:  Ann Saudi Med       Date:  2017 May-Jun       Impact factor: 1.526

4.  Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.

Authors:  Zijian Tian; Lingfeng Meng; Xin Wang; Tongxiang Diao; Maolin Hu; Miao Wang; Ming Liu; Jianye Wang
Journal:  BMC Cancer       Date:  2020-09-04       Impact factor: 4.430

5.  Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder.

Authors:  Ulku Kucuk; Emel Ebru Pala; Ebru Cakır; Ozlem Sezer; Umit Bayol; Rauf Taner Divrik; Ozgur Cakmak
Journal:  Cent European J Urol       Date:  2015-03-13

6.  Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience.

Authors:  Bartosz Dybowski; Krzysztof Ossoliński; Anna Ossolińska; Michał Peller; Ewa Bres-Niewada; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2015-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.